Assess whether a CMC change is a comparability or a new product (6d4a85)

Situation

A CRL citing manufacturing, not efficacy put phase-3 protocol with endpoint-sensitivity issues in front of CMC change-control owner in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Pharmacovigilance close is a CMC change is from phase-3 protocol with endpoint-sensitivity issues, and the live options are A CMC change is a comparability, A new product.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• CMC change-control owner can defend A CMC change is a comparability from phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend A CMC change is a comparability from phase-3 protocol with endpoint-sensitivity issues; A new product is what the extract actually supports after a CRL citing manufacturing, not efficacy.
• A CRL citing manufacturing, not efficacy never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close a CMC change is.
• Two facts in phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy conflict for CMC change-control owner; hold this Pharmacovigilance file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim CMC change-control owner would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMC change is for CMC change-control owner.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.